Trials / Completed
CompletedNCT04382885
Cariprazine Pediatric ASD PK Study
Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Participants With Autism Spectrum Disorder Aged 5-17 Years
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 5 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
This study will be a multi-center, open-label, parallel-group, multiple-dose study in up to 24 male and female participants aged 5 through 17 years, inclusive, with Autism Spectrum Disorder (ASD). The 24 participants will be enrolled into 1 of 4 cohorts (6 participants per cohort).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cariprazine | Oral Solution |
Timeline
- Start date
- 2020-06-26
- Primary completion
- 2021-12-10
- Completion
- 2021-12-10
- First posted
- 2020-05-11
- Last updated
- 2022-04-12
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04382885. Inclusion in this directory is not an endorsement.